4:14
Future therapies for AML: bispecifics and small molecule inhibitors
Farhad Ravandi
3:17
A pharmacoeconomic analysis of multiple myeloma treatment
Rafael Fonseca
4:20
What is the social value of CAR T-cell therapy in ALL?
Julia Snider
3:00
Key points in patient support across hematological oncology
Felice Bombaci
3:41
Computational methods are the future of biological research
Dominique Bonnet
2:00
Cost-effectiveness of MM treatment
Monika Engelhardt
1:53
The future of leukemia treatment leans towards immunotherapy
Robin Foà
2:01
Current and future therapies in mantle cell lymphoma
Simon Rule
5:02
Advances in the treatment of ALL: how far have we come?
Robin Foà
6:21
Gemtuzumab ozogamicin for AML: challenges and reapproval
Alan Burnett
1:45
Integrating genomics into clinical hematology
Willem Ouwehand
2:36
Hodgkin lymphoma: difficulties faced in geriatrics
Wendy Osborne
2:31
The importance of AML education amongst practitioners
Naval Daver
4:56
Value and cost in MM treatment
Vincent Rajkumar
3:27
Transplant in ALL after CAR T-cells & the role of MRD
David Maloney
1:13
Treatment challenges for young CLL patients
Matthew Davids
VJHemOnc is intended for Healthcare Professionals only

By choosing to continue, you are confirming that you are a healthcare professional

VJHO needs the contact information you provide to inform you about our latest hemonc news and videos, educational courses and industry supported content (some of which may be promotional in nature). You may unsubscribe from these communications at anytime. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy.

The content of VJHemOnc is intended for healthcare professionals